AT-43 MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND PHASE II STUDY COMPARING CEDIRANIB (AZD2171) PLUS GEFITINIB (IRESSA, ZD1839) WITH CEDIRANIB PLUS PLACEBO IN SUBJECTS WITH RECURRENT/PROGRESSIVE GLIOBLASTOMA

BACKGROUND: The vascular endothelial growth factor receptor (VEGFR) 2 tyrosine kinase inhibitor cediranib failed to improve outcome in recurrent glioblastoma in a randomized phase III trial (Batchelor et al.). One resistance mechanism for cediranib is through up-regulation of epidermal growth factor...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mulholland, Paul, Krell, Daniel, Khan, Iftekhar, McBain, Catherine, Patel, Chaya, Wanek, Katharina, Hopkins, Kirsten, Jeffries, Sarah, Jager, Rolf, Smith, Paul, Liu, Qi, Stupp, Roger, Tomlinson, Ian
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2014
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217822/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.42
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares